Costly leukemia pill wins UK green light after price cut

LONDON (Reuters) - A costly blood cancer pill sold in Europe by Johnson & Johnson will be made routinely available to certain patients in Britain with chronic lymphocytic leukemia, after the U.S. company agreed to cut the price.